SCHEMBL21653264

SCHEMBL21653264

O=C(Nc1cc(F)c(=O)n(CC(F)(F)F)c1)c1cc(Cl)c(Cl)s1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.36
▸ MAPK1 P28482 2/20 0.36
▸ GSK3B P49841 1/20 0.35
▸ DAO P14920 1/20 0.35
▸ AR P10275 2/20 0.33
▸ KMT2A Q03164 4/20 0.33
▸ MEN1 O00255 3/20 0.33
▸ RAB9A P51151 2/20 0.31
▸ HTT P42858 1/20 0.31
▸ THRB P10828 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ ESRRG P62508 1/20 0.31
▸ TLR7 Q9NYK1 1/20 0.31
▸ DDT P30046 1/20 0.31
▸ RXFP1 Q9HBX9 1/20 0.30
▸ IL2 P60568 1/20 0.30
▸ KDM4E B2RXH2 1/20 0.30
▸ NPC1 O15118 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21653072 0.91 KMT2A (0.38) MAPTMAPK1GSK3BDAOKMT2A
SCHEMBL21653156 0.89 PDE10A (0.38) MAPTMAPK1GSK3BDAOKMT2A
SCHEMBL21653232 0.86 MAPT (0.34) MAPTMAPK1ARKMT2AMEN1
SCHEMBL21653164 0.85 MAPT (0.37) MAPTMAPK1GSK3BDAOKMT2A
SCHEMBL21652918 0.85 GSK3B (0.36) MAPTMAPK1GSK3BDAOKMT2A
SCHEMBL21653233 0.83 MAPT (0.39) MAPTMAPK1GSK3BDAOKMT2A
SCHEMBL21653259 0.83 BACE1 (0.39) MAPTMAPK1KMT2AMEN1THRB
SCHEMBL21653120 0.78 GSK3B (0.39) MAPTMAPK1GSK3BDAOKMT2A
SCHEMBL21653160 0.78 MEN1 (0.35) MAPTMAPK1ARKMT2AMEN1
SCHEMBL21653150 0.76 GSK3B (0.36) MAPTGSK3BDAOKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020023657-A1 PYRIDIN-2-ONE COMPOUNDS USEFUL AS SMARCA2 ANTAGONISTS Epizyme, Inc. (US) 2020-01-30 — — WO disclosed
Send feedback